BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 28236475)

  • 1. Update of the Grupo Español de Leucemia Linfocítica Crónica clinical guidelines of the management of chronic lymphocytic leukemia.
    García-Marco JA; Delgado J; Hernández-Rivas JA; Ramírez Payer Á; Loscertales Pueyo J; Jarque I; Abrisqueta P; Giraldo P; Martínez R; Yáñez L; Terol MJ; González M; Bosch F;
    Med Clin (Barc); 2017 Apr; 148(8):381.e1-381.e9. PubMed ID: 28236475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current strategies to create tailored and risk-adapted therapies for CLL patients.
    Cramer P; Eichhorst B; Reinhardt HC; Hallek M
    Best Pract Res Clin Haematol; 2016 Mar; 29(1):111-121. PubMed ID: 27742065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Current diagnosis and treatment of chronic lymphocytic leukaemia].
    Cramer P; von Tresckow J; Eichhorst B; Hallek M
    Dtsch Med Wochenschr; 2020 Aug; 145(16):1139-1144. PubMed ID: 32791549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic lymphocytic leukaemia.
    Hallek M; Shanafelt TD; Eichhorst B
    Lancet; 2018 Apr; 391(10129):1524-1537. PubMed ID: 29477250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacotherapeutic Management of Chronic Lymphocytic Leukaemia in Patients with Comorbidities: New Agents, New Hope.
    Goede V; Hallek M
    Drugs Aging; 2015 Nov; 32(11):877-86. PubMed ID: 26446155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemoimmunotherapy Versus Targeted Treatment in Chronic Lymphocytic Leukemia: When, How Long, How Much, and in Which Combination?
    Brown JR; Hallek MJ; Pagel JM
    Am Soc Clin Oncol Educ Book; 2016; 35():e387-98. PubMed ID: 27249745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia.
    Rogers KA; Huang Y; Ruppert AS; Awan FT; Heerema NA; Hoffman C; Lozanski G; Maddocks KJ; Moran ME; Reid MA; Lucas M; Woyach JA; Whitlow WT; Jones JA; Byrd JC
    Blood; 2018 Oct; 132(15):1568-1572. PubMed ID: 30111609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel agents in the treatment of chronic lymphocytic leukemia: a review about the future.
    Desai AV; El-Bakkar H; Abdul-Hay M
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):314-22. PubMed ID: 25445466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Chronic Lymphocytic Leukemia: Ibrutinib, Idelalisib, and Venetoclax.
    Waldron M; Winter A; Hill BT
    Clin Pharmacokinet; 2017 Nov; 56(11):1255-1266. PubMed ID: 28343293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How should we sequence and combine novel therapies in CLL?
    Davids MS
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):346-353. PubMed ID: 29222277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three newly approved drugs for chronic lymphocytic leukemia: incorporating ibrutinib, idelalisib, and obinutuzumab into clinical practice.
    Sanford DS; Wierda WG; Burger JA; Keating MJ; O'Brien SM
    Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):385-91. PubMed ID: 25817936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An update of venetoclax and obinutuzumab in chronic lymphocytic leukemia.
    Salvaris R; Opat S
    Future Oncol; 2021 Feb; 17(4):371-387. PubMed ID: 33064021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ibrutinib: searching for a partner drug.
    Kater AP; Brown JR
    Lancet Oncol; 2019 Jan; 20(1):3-5. PubMed ID: 30522966
    [No Abstract]   [Full Text] [Related]  

  • 14. [Targeted treatment of chronic lymphocytic leukaemia].
    Niemann CU
    Ugeskr Laeger; 2014 Apr; 176(15):. PubMed ID: 25350143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Idelalisib, ibrutinib show benefits in CLL.
    Cancer Discov; 2014 Apr; 4(4):382. PubMed ID: 24706642
    [No Abstract]   [Full Text] [Related]  

  • 16. Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment.
    Hallek M
    Am J Hematol; 2017 Sep; 92(9):946-965. PubMed ID: 28782884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Chronic lymphatic leukemia].
    Bergmann M; Wendtner CM
    Dtsch Med Wochenschr; 2015 Apr; 140(7):479-82. PubMed ID: 25826029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations.
    Soumerai JD; Ni A; Darif M; Londhe A; Xing G; Mun Y; Kay NE; Shanafelt TD; Rabe KG; Byrd JC; Chanan-Khan AA; Furman RR; Hillmen P; Jones J; Seymour JF; Sharman JP; Ferrante L; Mobasher M; Stark T; Reddy V; Dreiling LK; Bhargava P; Howes A; James DF; Zelenetz AD
    Lancet Haematol; 2019 Jul; 6(7):e366-e374. PubMed ID: 31109827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted therapy in the treatment of chronic lymphocytic leukemia: facts, shortcomings and hopes for the future.
    Molica S
    Expert Rev Hematol; 2017 May; 10(5):425-432. PubMed ID: 28349723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatment.
    Gaidano G; Rossi D
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):329-337. PubMed ID: 29222275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.